SAM-315

DRUG3 trials

Sponsors

Wyeth is now a wholly owned subsidiary of Pfizer

Conditions

Alzheimer Disease

Phase 1

Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of SAM-315

TerminatedNCT00474552

Wyeth is now a wholly owned subsidiary of PfizerAlzheimer Disease

Start: 2007-06-30End: 2007-10-31Target: 56Updated: 2008-02-18

Study Evaluating the Safety, Tolerability, Pharmacokinetics (PK), and Pharmacodynamics (PD) of SAM-315 in Healthy Adults

CompletedNCT00479440

Wyeth is now a wholly owned subsidiary of PfizerAlzheimer Disease

Start: 2006-08-31End: 2007-03-31Target: 56Updated: 2007-12-05

Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of SAM-315 in Healthy Japanese Males

CompletedNCT00480467

Wyeth is now a wholly owned subsidiary of PfizerAlzheimer Disease

Start: 2006-09-30End: 2007-08-31Target: 32Updated: 2007-12-05